PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Equity / COM
Total 13F shares
64,821,246
Share change
+564,023
Total reported value
$521,178,303
Put/Call ratio
47%
Price per share
$8.04
Number of holders
150
Value change
+$4,962,303
Number of buys
73
Number of sells
50

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q2 2018

As of 30 Jun 2018, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 150 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 64,821,246 shares. The largest 10 holders included BlackRock Inc., FEDERATED INVESTORS INC /PA/, EAGLE ASSET MANAGEMENT INC, VANGUARD GROUP INC, STATE STREET CORP, CARILLON TOWER ADVISERS, INC., FARALLON CAPITAL MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, ARDSLEY ADVISORY PARTNERS, and PINNACLE ASSOCIATES LTD. This page lists 150 institutional shareholders reporting positions in this security for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.